Bivalent nanobodies in bi-specific CAR-T cells significantly reduced tumor escape by simultaneously recognizing two targets, for example, CD20 plus either HER2, PD-L1, or EIIIB, on the cells with a resultant loss of target expression [13,14]. The gene discussed is ERBB2; the disease is neoplasm.